Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow Transplant

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Annals of Internal Medicine

• Publication date

  1993-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.7326/0003-4819-118-3-199302010-00003PMID 8380242
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.

  1992cited by this paper
• A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.

  1991cited by this paper
• A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow Transplants

  1991influential reference
• Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.

  1991influential reference
• Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection

  1991cited by this paper
• Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia.

  1991cited by this paper
• Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial.

  1990cited by this paper
• Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia.

  1990cited by this paper
• RAPID DETECTION OF HUMAN CYTOMEGALOVIRUS DNA IN PERIPHERAL BLOOD LEUKOCYTES OF VIREMIC TRANSPLANT RECIPIENTS BY THE POLYMERASE CHAIN REACTION

  1989cited by this paper
• Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants.

  1988cited by this paper
• Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients.

  1988cited by this paper
• Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients.

  1988cited by this paper
• Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation.

  1988cited by this paper
• Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin.

  1988cited by this paper
• Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients.

  1988cited by this paper
• Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes

  1988cited by this paper
• Risk factors for cytomegalovirus infection after human marrow transplantation.

  1986cited by this paper
• Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen

  1984cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• HCMV infection depends on EGLN1-mediated mitochondrial activation to increase dNTP pools for viral DNA replication

  2025cites this paper
• CMV infections after HSCT: prophylaxis and treatment

  2025cites this paper
• Tackling CMV in Transplant Recipients: Past, Present, and Future

  2025cites this paper
• RAF1 promotes successful human cytomegalovirus replication and is regulated by AMPK-mediated phosphorylation during infection

  2025cites this paper
• Standing on the Shoulders of Imperfect Humans (Val)ganciclovir Dosing for Cytomegalovirus: Revisiting the 2005 Wiltshire et al. PK/PD target

  2025cites this paper
• Safety and Efficacy of Antiviral Drugs and Vaccines in Pregnant Women: Insights from Physiologically Based Pharmacokinetic Modeling and Integration of Viral Infection Dynamics

  2024cites this paper
• Nephrotoxicity of Intravenous Ganciclovir in Pediatric Hematopoietic Cell Transplant Recipients

  2024cites this paper
• Differences in safety profiles of anti-herpesvirus medications: a real-world pharmacovigilance study based on the FAERS database

  2024cites this paper
• Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan

  2024influential citation
• Antimicrobials in patients with hematologic malignancies and recipients of hematopoietic cell transplantation and other cellular therapies

  2023cites this paper
• Cytomegalovirus-induced inactivation of TSC2 disrupts the coupling of fatty acid biosynthesis to glucose availability resulting in a vulnerability to glucose limitation

  2023cites this paper
• Raf1 promotes successful Human Cytomegalovirus replication and is regulated by AMPK-mediated phosphorylation during infection

  2023cites this paper
• Cytomegalovirus-induced inactivation of TSC2 disrupts the coupling of fatty acid biosynthesis to glucose availability resulting in a vulnerability to glucose starvation

  2023cites this paper
• Case Report: Fatal cytomegalovirus pneumonia after CAR-T cell therapy in the long-term follow-up

  2023cites this paper
• M-CSF induces a coordinated myeloid and NK cell differentiation program protecting against CMV after hematopoietic cell transplantation

  2023cites this paper
• Medical emergencies in pediatric blood & marrow transplant and cellular therapies

  2023cites this paper
• Efficacy, Safety, and Cost-effectiveness Analysis of Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients

  2023cites this paper
• M‐CSF directs myeloid and NK cell differentiation to protect from CMV after hematopoietic cell transplantation

  2023cites this paper
• Management of Cytomegalovirus infection in allogeneic hematopoietic stem cell transplants.

  2023cites this paper
• Prevention and management of human cytomegalovirus in pediatric HSCT recipients: A review

  2022cites this paper
• Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide

  2022cites this paper
• Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation

  2022cites this paper
• Human cytomegalovirus-specific T-cell reconstitution and late-onset cytomegalovirus infection in hematopoietic stem cell transplant recipients following letermovir prophylaxis.

  2022cites this paper
• Letermovir as CMV Prophylaxis in a Pediatric Cohort: A Retrospective Analysis: Letermovir in Pediatric HCT Patients.

  2022cites this paper
• Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression.

  2022cites this paper
• Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment.

  2022cites this paper
• Research progress of purine competitive antagonists.

  2022cites this paper
• The Ten Most Common Questions on Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients

  2022cites this paper
• Otolog Kök Hücre Transplantasyonunda Sitomegalovirüs (CMV) ve Hepatit B (HBV) Reaktivasyonu: Tek Merkez Deneyimi

  2022cites this paper
• Detection of human herpesvirus 6 DNA and chromosomal integration after allogeneic hematopoietic stem cell transplantation: A retrospective single center analysis

  2022cites this paper
• Relationship between renal dysfunction and electrolyte abnormalities in hematopoietic stem cell transplant patients treated with foscarnet

  2021cites this paper
• Ganciclovir therapeutic drug monitoring in transplant recipients

  2021cites this paper
• Contributions of the Human Cytomegalovirus UL30-Associated Open Reading Frames to Infection

  2021cites this paper
• Prophylactic Pretransplant Ganciclovir to Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation

  2021cites this paper
• Early T cell reconstitution and cytokine profile may help to guide a personalized management of human cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.

  2021cites this paper
• Safety and Effectiveness of Letermovir in Allogenic Hematopoietic Stem Cell Transplantation Recipients: Interim Report of Post-marketing Surveillance in Japan

  2021cites this paper
• Pre-engraftment clinically significant CMV infection after allogeneic hematopoietic stem cell transplantation and its impact on engraftment

  2021cites this paper
• American Society for Transplantation and Cellular Therapy Series: #3-Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation.

  2021cites this paper
• Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience

  2021cites this paper
• A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients

  2021cites this paper
• Clinical characteristics and viral load patterns in children with cytomegalovirus gastrointestinal disease after allogeneic hematopoietic stem cell transplantation

  2021cites this paper
• Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status.

  2020cites this paper
• Interplay Between Calcium and AMPK Signaling in Human Cytomegalovirus Infection

  2020cites this paper
• First-line therapy with donor-derived HCMV-specific T cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic stem cell transplantation.

  2020cites this paper
• Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre‐transplant predictors of survival, reactivation, and spontaneous clearance

  2020cites this paper
• Low-level Cytomegalovirus Antigenemia Promotes Protective Cytomegalovirus Antigen Specific T-Cells after Allogeneic Hematopoietic Cell Transplantation.

  2020cites this paper
• Targeting human cytomegalovirus IE genes by CRISPR/Cas9 nuclease effectively inhibits viral replication and reactivation

  2020cites this paper
• Current Understanding of Cytomegalovirus Reactivation in Critical Illness.

  2020cites this paper
• Cell therapy for cytomegalovirus infection

  2020cites this paper
• Elevation of cytomegalovirus antigenemia predicts serious infection and death in patients receiving immunosuppressive therapies for autoimmune diseases

  2020cites this paper
• Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice. A Retrospective Single Center Cohort Study.

  2020influential citation
• CMV viral load kinetics as surrogate endpoints after allogeneic transplantation

  2020influential citation
• Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation.

  2020cites this paper
• Cytomegalovirus viral load kinetics as surrogate endpoints after allogeneic transplantation.

  2020cites this paper
• Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for hematological disease: systematic review and meta-analysis.

  2020cites this paper
• Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients: Prevention, Diagnosis, and Treatment

  2020cites this paper
• Cost‐effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective

  2020cites this paper
• Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation

  2020cites this paper
• Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients

  2019cites this paper
• Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).

  2019cites this paper
• A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation

  2019cites this paper
• CMV viremia and death after HCT: More complex than "to have and have not"?

  2019cites this paper
• Update on prevention of cytomegalovirus in hematopoietic cell transplantation

  2019cites this paper
• Cytomegalovirus Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patient.

  2019cites this paper
• Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient

  2019cites this paper
• Cytomegalovirus

  2019cites this paper
• Infection Control Strategies in Transplant Populations

  2019cites this paper
• CMV Prevention and Treatment in Transplantation: What’s New in 2019

  2019cites this paper
• Safety profile of the concomitant use of foscarnet and aerosolized pentamidine in allogeneic hematopoietic stem cell transplantation recipients

  2019cites this paper
• Prophylaxis and Management of Infectious Complications After Hematopoietic Cell Transplantation

  2019cites this paper
• Meal for Two: Human Cytomegalovirus-Induced Activation of Cellular Metabolism

  2019cites this paper
• Mixed vs full donor engraftment early after hematopoietic cell transplant: Impact on incidence and control of cytomegalovirus infection

  2019cites this paper
• Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation

  2019cites this paper
• An update on the treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

  2019cites this paper
• MANAGEMENTS OF CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

  2019cites this paper
• Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation.

  2018cites this paper
• Cytotect®CP as salvage therapy in patients with CMV infection following allogeneic hematopoietic cell transplantation: a multicenter retrospective study

  2018cites this paper
• EBV-PTLD, Adenovirus, and CMV in Pediatric Allogeneic Transplants With Alemtuzumab as Part of Pretransplant Conditioning: A Retrospective Single Center Study

  2018cites this paper
• Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.

  2018cites this paper
• A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation

  2018cites this paper
• 295 – Antiviral Agents

  2018cites this paper
• Immune Monitoring for CMV in Transplantation

  2018cites this paper
• Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation

  2018cites this paper
• Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients

  2018cites this paper
• Infections in Hematopoietic Stem Cell Transplant Recipients

  2018cites this paper
• Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation.

  2018cites this paper
• Infections in Allogeneic Stem Cell Transplantation

  2018cites this paper
• Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis

  2018cites this paper
• New Developments in the Management of Cytomegalovirus Infection After Transplantation

  2018cites this paper
• Highlights in cytomegalovirus from the 2018 BMT Tandem Meetings: commentary.

  2018cites this paper
• Invasive fungal disease and cytomegalovirus infection: is there an association?

  2018cites this paper
• A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection

  2018cites this paper
• Management of Infections in the Immunocompromised Host

  2018cites this paper
• Complications and Results

  2017cites this paper
• Manipulation of Viral MicroRNAs as a Potential Antiviral Strategy for the Treatment of Cytomegalovirus Infection

  2017cites this paper
• Cytomegalovirus Treatment in Pediatric Hematopoietic Stem Cell Transplant Patients

  2017cites this paper
• Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic‐Cell Transplantation

  2017cites this paper
• Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation

  2017cites this paper
• Nouvelles perspectives thérapeutiques dans l’infection à cytomégalovirus

  2017cites this paper
• Improved outcome of haploidentical transplantation in severe aplastic anemia using reduced-intensity fludarabine-based conditioning

  2017cites this paper